TU-7710

Global Acquired Hemophilia A pipeline comprises over 10 companies developing innovative therapies across various clinical stages, according to DelveInsight's 2025 report.

TiumBio's oral GnRH antagonist merigolix successfully met primary endpoints in Phase 2 trials for uterine fibroids, demonstrating significant reduction in heavy menstrual bleeding across all dosage groups compared to placebo.

Tiumbio's TU7710, a novel hemophilia treatment candidate, successfully completed Phase 1a clinical trials, demonstrating high safety and tolerability in healthy male participants.

Several companies are actively involved in developing therapies for Hemophilia B, with Belief Biomed's drug candidates reaching Phase III clinical trials.

TiumBio has dosed the first patient in a Phase 2 clinical trial of TU2218, an oral dual inhibitor targeting TGFR1 and VEGFR2.